Menu
Search
|

Menu

Close
X

Aimmune Therapeutics Inc AIMT.OQ (NASDAQ Stock Exchange Global Select Market)

24.22 USD
-0.96 (-3.81%)
As of 2:29 AM IST
chart
Previous Close 25.18
Open 25.35
Volume 226,229
3m Avg Volume 151,551
Today’s High 25.71
Today’s Low 24.02
52 Week High 41.75
52 Week Low 24.02
Shares Outstanding (mil) 50.54
Market Capitalization (mil) 1,281.57
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.719
FY17
-2.074
FY16
-1.883
FY15
-1.006
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.60
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
5.40
5.11
Price to Cash Flow (TTM)
vs sector
--
23.53
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-50.47
15.05
Return on Equity (TTM)
vs sector
-50.82
16.62

EXECUTIVE LEADERSHIP

Mark McDade
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Jayson Dallas
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Eric Bjerkholt
Chief Financial Officer, Since 2017
Salary: $268,333.00
Bonus: $116,000.00
Mary Rozenman
Senior Vice President - Strategy and Corporate Development, Since 2016
Salary: --
Bonus: --
Douglas Sheehy
General Counsel, Secretary, Since 2016
Salary: $360,250.00
Bonus: $155,600.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8000 Marina Blvd Ste 300
BRISBANE   CA   94005-1884

Phone: +1650.6145220

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

SPONSORED STORIES